Investor Presentation
RPGLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
RPG Life Sciences filed its investor presentation for the Annual Investor Conference 2026 (May 26, 2026). The company reported FY26 revenue of Rs 707.5 crore (up 8.3% YoY) with EBITDA of Rs 172.7 crore (24.4% margin), EPS of Rs 69.6, ROCE of 28.5%, and ROE of 21.1%. Over the 5-year period FY21–FY26, revenue grew at a 12.7% CAGR and PBT margin expanded from 13.8% to 21.2%. The company holds cash reserves of Rs 276.5 crore and has deployed Rs 185+ crore in capex over 5 years. Domestic Formulations (69% of sales) outperformed the Indian Pharma Market at ~1.6x pace, with Naprosyn growing 16% in FY26. The strategic roadmap includes building mega brands (Rs 100+ cr Naprosyn, Rs 100+ cr Immuno portfolio, Rs 50+ cr MABs portfolio), expanding via strategic acquisitions, and growing API and International Formulations businesses. ICRA reaffirmed ratings at A+/A1 stable.
Strong operational performance and margin expansion reflect solid execution in a competitive pharma market. The disclosed strategic targets and acquisition plans suggest management is actively positioning for the next phase of growth, which could support a re-rating if targets are met.